Ipclogo (Ipclogo)
Levetiracetam
Product Images NDC 35208-032
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 35208-032). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Intellipharmaceutics Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Lev500mg (Lev500mg)
Levetiracetam Extended-Release Tablets USP 500 mg label. The label indicates once daily dosing, contains 60 tablets, and is marked Rx only. Manufactured by IntelliPharmaCeutics Corp. Dosage and storage instructions are provided, along with a pharmacist warning to dispense a medication guide to each patient.*
Lev750mg (Lev750mg)
Label for Levetiracetam Extended-Release Tablets USP 750 mg by IntelliPharmaCeutics Corp. The label indicates once daily dosing for 60 tablets, Rx only. The label includes storage instructions, a pharmacist warning, and the manufacturer's location in Toronto, Canada. NDC 35208-032-60 is shown.*
Levfig1 (Levfig1)
A bar graph comparing the percentage of patients with an unspecified outcome among three groups: Placebo, Immediate-release Levetiracetam 1000 mg/day, and Immediate-release Levetiracetam 3000 mg/day. The graph shows higher percentages for the drug groups compared to placebo.*
Levfig2 (Levfig2)
A bar chart showing the percentage of CPR patients for three groups: Placebo (6.3%, N=111), Immediate-release Levetiracetam 2000mg/day (20.8%, N=106), and Immediate-release Levetiracetam 2000mg/day (35.2%, N=105). The chart compares the treatment effects across these groups.*
Levfig3 (Levfig3)
A bar graph comparing the percentage of patients between two groups: Placebo (N=104) with 14.4%, and Immediate-release Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis indicates the percentage of patients, ranging from 0% to 45%.*
Levfig4 (Levfig4)
A bar chart comparing the percentage of patients in two groups: Placebo (N=97) with 19.6% and Immediate-release Levetiracetam (N=101) with 44.6%. The chart visually displays a higher patient percentage in the immediate-release Levetiracetam group versus the placebo group.*
Levstructure (Levstructure)
Chemical structure diagram representing the active ingredient in Levetiracetam Extended-release. The diagram shows the molecular arrangement of atoms including nitrogen, oxygen, carbon, hydrogen, and a side chain.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
